MedTrace Logo

An Open-label Study of EZYPRO® in Atrial Fibrillation Detection on ESUS Patients

NCT05089435 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2022-05-10

No results posted yet for this study

Summary

The aim of the study is to evaluate the effectiveness and safety of the 14-day continuous ECG patch monitor (EZYPRO®) compared with a 24-hour Holter monitor in the detection of atrial fibrillation (AF) among ESUS patients.

Conditions

Interventions

DEVICE

EZYPRO® ECG Recorder

EZYPRO is an ECG monitoring patch designed to enhance the arrhythmia detection rate by applying 14 days in a home setting environment.

Sponsors & Collaborators

  • Sigknow Biomedical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Li Ming Lien, PhD · Shin Kong Wu Ho-Su Memorial Hospital

  • Li Kai Tsai, PhD · National Taiwan University Hospital Hsin-Chu Branch

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-28
Primary Completion
2023-03-31
Completion
2023-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05089435 on ClinicalTrials.gov